Top 15 Drugs Ranked on 2022 Worldwide Sales
Finally, Evaluate looks at the individual products that will bring in the greatest revenue from here to 2022. They
are dominated by oncologics (Revlimid, Keytruda, Opdivo, Ibrance and others), while HIV meds (Triumeq,
Bictegravir) will also be in demand, as will autoimmune treatments (Humira), the pneumococcal medication
Prevnar, and others. The only product on the list not aimed at a serious or life-threatening condition is Botox,
originally prescribed for migraines but now largely used to erase facial lines and crows feet.
EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight
into biotech and pharmaceutical performance.
EvaluateMed Tech® sets a new standard in commercial analysis and consensus forecasts of the
global medical device and diagnostic industry.